IDEXX Laboratories (FRA:IX1) Piotroski F-Score: 8 (As of Jun. 25, 2026) — 14% Above Median


FRA:IX1 IDEXX Laboratories Inc FRA:IX1
96 GF Score
Price €473.80
GF Value €552.99
Valuation Modestly Undervalued
View Full Analysis

What is IDEXX Laboratories Piotroski F-Score?

IDEXX Laboratories FRA:IX1 -0.19% 96 Piotroski F-Score is 8 as of Jun. 25, 2026, which is 14% above its 10-year median of 7.00. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €552.99 (Modestly Undervalued). Among 211 Medical Diagnostics & Research companies, IDEXX Laboratories ranks better than 98.58% on this metric.

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

IDEXX Laboratories has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for IDEXX Laboratories's Piotroski F-Score or its related term are showing as below:

FRA:IX1' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 7   Max: 9
Current: 8

During the past 13 years, the highest Piotroski F-Score of IDEXX Laboratories was 9. The lowest was 4. And the median was 7.

IDEXX Laboratories  (FRA:IX1) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


IDEXX Laboratories Piotroski F-Score Related Terms


IDEXX Laboratories Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for IDEXX Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEXX Laboratories Piotroski F-Score Chart

IDEXX Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 5.00 7.00 6.00 8.00

IDEXX Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 5.00 7.00 8.00 8.00

FRA:IX1 vs A, WAT, NTRA: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, IDEXX Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEXX Laboratories Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where IDEXX Laboratories's Piotroski F-Score falls into.


FRA:IX1
96GF Score
IDEXX Laboratories Inc FRA:IX1
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 254.888 + 233.968 + 211.953 + 240.856 = €942 Mil.
Cash Flow from Operations was 161.039 + 342.794 + 303.819 + 230.305 = €1,038 Mil.
Revenue was 961.899 + 941.664 + 931.354 + 986.809 = €3,822 Mil.
Gross Profit was 602.333 + 582.218 + 562.029 + 625.169 = €2,372 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(2972.662 + 2887.798 + 2885.479 + 2861.548 + 2928.455) / 5 = €2907.1884 Mil.
Total Assets at the begining of this year (Mar25) was €2,973 Mil.
Long-Term Debt & Capital Lease Obligation was €345 Mil.
Total Current Assets was €1,258 Mil.
Total Current Liabilities was €1,124 Mil.
Net Income was 188.864 + 209.79 + 206.422 + 224.476 = €830 Mil.

Revenue was 932.324 + 878.964 + 911.345 + 923.545 = €3,646 Mil.
Gross Profit was 575.199 + 537.03 + 544.98 + 576.626 = €2,234 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(3085.234 + 3172.411 + 3019.04 + 3145.238 + 2972.662) / 5 = €3078.917 Mil.
Total Assets at the begining of last year (Mar24) was €3,085 Mil.
Long-Term Debt & Capital Lease Obligation was €506 Mil.
Total Current Assets was €1,219 Mil.
Total Current Liabilities was €1,051 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

IDEXX Laboratories's current Net Income (TTM) was 942. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

IDEXX Laboratories's current Cash Flow from Operations (TTM) was 1,038. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=941.665/2972.662
=0.316775

ROA (Last Year)=Net Income/Total Assets (Mar24)
=829.552/3085.234
=0.26887815

IDEXX Laboratories's return on assets of this year was 0.316775. IDEXX Laboratories's return on assets of last year was 0.26887815. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

IDEXX Laboratories's current Net Income (TTM) was 942. IDEXX Laboratories's current Cash Flow from Operations (TTM) was 1,038. ==> 1,038 > 942 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=344.79/2907.1884
=0.11859912

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=505.793/3078.917
=0.16427627

IDEXX Laboratories's gearing of this year was 0.11859912. IDEXX Laboratories's gearing of last year was 0.16427627. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=1257.775/1124.371
=1.11864767

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=1218.792/1050.997
=1.15965317

IDEXX Laboratories's current ratio of this year was 1.11864767. IDEXX Laboratories's current ratio of last year was 1.15965317. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

IDEXX Laboratories's number of shares in issue this year was 80.162. IDEXX Laboratories's number of shares in issue last year was 81.922. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2371.749/3821.726
=0.6205963

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2233.835/3646.178
=0.61265111

IDEXX Laboratories's gross margin of this year was 0.6205963. IDEXX Laboratories's gross margin of last year was 0.61265111. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=3821.726/2972.662
=1.28562413

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=3646.178/3085.234
=1.18181571

IDEXX Laboratories's asset turnover of this year was 1.28562413. IDEXX Laboratories's asset turnover of last year was 1.18181571. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+1+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

IDEXX Laboratories has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 8 mean?
IDEXX Laboratories (FRA:IX1) has a Piotroski F-Score of 8 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on IDEXX Laboratories and its competitors. This is 14% above median its historical median of 7.00. Over the past decade, IDEXX Laboratories' Piotroski F-Score has ranged from 4.00 to 9.00. According to the industry distribution chart, IDEXX Laboratories ranks #3 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 1.4%.
Is IDEXX Laboratories' Piotroski F-Score too high?
IDEXX Laboratories' current Piotroski F-Score of 8 is 14% above median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 9.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. IDEXX Laboratories' value of 8 is 60% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #3 out of 211 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Piotroski F-Score compare to A and WAT?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #3 out of 211 companies for Piotroski F-Score. This places IDEXX Laboratories in the top 1% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. IDEXX Laboratories' value of 8 is 60% above this benchmark. Historically, IDEXX Laboratories' own Piotroski F-Score has ranged from 4.00 to 9.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current Piotroski F-Score of 8 is 60% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current Piotroski F-Score is 8, which is 14% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €552.99, compared to a current price of €473.80 — trading 14.3% below its estimated fair value. The current Piotroski F-Score is 8, which is 14% above median its 10-year median of 7.00 and 60% above the Medical Diagnostics & Research industry median of 5.00. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Piotroski F-Score is 8 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?

Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued. The current stock price of €473.80 is trading 14.3% below its estimated GF Value™ of €552.99. GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.

Key valuation signals for FRA:IX1:

  • Piotroski F-Score: 8 (14% above median its 10-year median of 7.00)
  • GF Value™: €552.99 vs. price of €473.80 (14.3% below fair value)
  • GF Score™: 96/100
  • Industry Position: 60% above the Medical Diagnostics & Research median (#3 of 211)

No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IDEXX Laboratories Business Description

Address One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score

Get the complete analysis for FRA:IX1

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€473.80
Price
€552.99
GF Value